Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;49(1):141-149.
doi: 10.4143/crt.2016.133. Epub 2016 May 18.

Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Seung Hyeun Lee  1 , Sue In Choi  2 , Ji Sung Lee  3 , Chul Hwan Kim  4 , Won Jai Jung  2 , Eun Joo Lee  2 , Kyung Hoon Min  2 , Gyu Young Hur  2 , Seung Heon Lee  2 , Sung Yong Lee  2 , Je Hyeong Kim  2 , Sang Yeub Lee  2 , Chol Shin  2 , Jae Jeong Shim  2 , Kyung Ho Kang  2 , Kwang Ho In  2
Affiliations

Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy

Seung Hyeun Lee et al. Cancer Res Treat. 2017 Jan.

Abstract

Purpose: Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.

Materials and methods: Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated.

Results: A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology.

Conclusion: Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.

Keywords: Biomarkers; Drug therapy; Lung neoplasms; Platinum; Prognosis; Reactive oxygen species.

PubMed Disclaimer

Conflict of interest statement

relevant to this article was not reported.

Figures

Fig. 1.
Fig. 1.
Representative samples of immunochemical staining for Romo1 with different H scores (×200). Romo1 was primarily detected in the cytoplasm of adenocarcinoma and squamous cell carcinoma cells. (A) H score of 50. (B) H score of 150. (C) H score of 250. Romo1, reactive oxygen species modulator 1; H scores, histological scores; ADC, adenocarcinoma; SQCC, squamous cell carcinoma.
Fig. 2.
Fig. 2.
Kaplan-Meier survival curves for progression-free survival (PFS) (A) and overall survival (OS) (B) in the overall population. p-values were determined using the log-rank test. Romo1, reactive oxygen species modulator 1.
See this image and copyright information in PMC

References

    1. Jemal A. Global burden of cancer: opportunities for prevention. Lancet. 2012;380:1797–9. - PubMed
    1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71. - PubMed
    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8. - PubMed
    1. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323:561–5. - PubMed
    1. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5240–7. - PubMed

MeSH terms

LinkOut - more resources